Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

242 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Optimizing the Use of Gene Expression Profiling in Early-Stage Breast Cancer.
Kim HS, Umbricht CB, Illei PB, Cimino-Mathews A, Cho S, Chowdhury N, Figueroa-Magalhaes MC, Pesce C, Jeter SC, Mylander C, Rosman M, Tafra L, Turner BM, Hicks DG, Jensen TA, Miller DV, Armstrong DK, Connolly RM, Fetting JH, Miller RS, Park BH, Stearns V, Visvanathan K, Wolff AC, Cope L. Kim HS, et al. Among authors: armstrong dk. J Clin Oncol. 2016 Dec 20;34(36):4390-4397. doi: 10.1200/JCO.2016.67.7195. Epub 2016 Oct 31. J Clin Oncol. 2016. PMID: 27998227 Free PMC article.
A phase I toxicity and feasibility trial of sequential dose-dense induction chemotherapy with doxorubicin, paclitaxel, and 5-fluorouracil followed by high dose consolidation for high-risk primary breast cancer.
Emens LA, Kennedy MJ, Fetting JH, Davidson NE, Garrett E, Armstrong DK. Emens LA, et al. Among authors: armstrong dk. Breast Cancer Res Treat. 2002 Nov;76(2):145-56. doi: 10.1023/a:1020566218512. Breast Cancer Res Treat. 2002. PMID: 12452452 Clinical Trial.
Feasibility trial of partial breast irradiation with concurrent dose-dense doxorubicin and cyclophosphamide in early-stage breast cancer.
Zellars RC, Stearns V, Frassica D, Asrari F, Tsangaris T, Myers L, DiPasquale S, Lange JR, Jacobs LK, Emens LA, Armstrong DK, Fetting JH, Garrett-Mayer E, Davidson NE, Wolff AC. Zellars RC, et al. Among authors: armstrong dk. J Clin Oncol. 2009 Jun 10;27(17):2816-22. doi: 10.1200/JCO.2008.20.0139. Epub 2009 Mar 30. J Clin Oncol. 2009. PMID: 19332718 Free PMC article.
African American women who receive primary anthracycline- and taxane-based chemotherapy for triple-negative breast cancer suffer worse outcomes compared with white women.
Balmanoukian A, Zhang Z, Jeter S, Slater S, Armstrong DK, Emens LA, Fetting JH, Wolff AC, Davidson NE, Jacobs L, Lange J, Tsangaris TN, Zellars R, Gabrielson E, Stearns V. Balmanoukian A, et al. Among authors: armstrong dk. J Clin Oncol. 2009 Aug 1;27(22):e35-7; author reply e38-9. doi: 10.1200/JCO.2008.21.5509. Epub 2009 Jun 29. J Clin Oncol. 2009. PMID: 19564528 Free PMC article. No abstract available.
Pathologic complete response to preoperative sequential doxorubicin/cyclophosphamide and single-agent taxane with or without trastuzumab in stage II/III HER2-positive breast cancer.
Chumsri S, Jeter S, Jacobs LK, Nassar H, Armstrong DK, Emens LA, Fetting JH, Lange JR, Riley C, Tsangaris TN, Wolff AC, Zellars R, Zhang Z, Stearns V. Chumsri S, et al. Among authors: armstrong dk. Clin Breast Cancer. 2010 Feb;10(1):40-5. doi: 10.3816/CBC.2010.n.005. Clin Breast Cancer. 2010. PMID: 20133257
242 results